OMass’ OdyssION™ drug discovery platform advances in
OMassit’s OdyssION™ Drug Discovery Platform Made progress in the dope of the inrugableincluding Gasdermin D
BeefFord, UUK – 28 February 2022 – OMass Therapeutics (“OMass” or “the Company”), a biotechnology company identifying drugs against highly validated target ecosystems, is pleased to provide an update on its proprietary drug discovery platform, OdyssION™ and its progress in identifying new drugs for refractory or inadequate diseases. drugged membrane and complex-bound proteins. Early data and progress from its gasdermin D program underscores the power of the platform.
The OdyssION™ platform enables OMass to interrogate how a protein interacts with its native ecosystem, regardless of the bewildering complexity of the cell. The result is cell system fidelity with cell-free precision.
The platform integrates new biochemistry techniques, next-generation native mass spectrometry and personalized chemistry. This allows us to preserve downstream partners of a target (eg, lipids and other endogenous regulatory molecules) and distill biology into its essential elements, the physical interactions within a native ecosystem. These interactions can then be measured at high resolution with our patent-protected native mass spectrometry technology, originally pioneered by OMass founder Professor Dame Carol Robinson. Carol’s achievements were recognized last year when she was awarded the 2022 Louis-Jeantet Prize for Medicine and the 2022 Benjamin Franklin Medal for Chemistry.
The OdyssION™ platform was instrumental in OMass’ search for a gasdermin-D (GSDMD) inhibitor. GSDMD is a pore-forming protein that lies at the heart of multiple inflammatory cell death pathways and has been shown to be unusable to date. However, thanks to the power of the OdyssION™ platform, OMass was able to identify a series of functional successes. The Company’s current primary indication for its GSDMD program is Familial Mediterranean Fever, an inherited autoinflammatory disease that causes recurrent episodes of fever and stomach, joint and muscle pain.
Benefits of the OdyssION™ platform and how these helped OMass in its search for a GSDMD inhibitor include:
- Linking connection and function: The GSDMD-caspase complex can be observed with the mass spectrometer, which allows OMass to measure the impact of a hit on the formation of the complex
- Querying a high-precision native ecosystem: a new cation necessary for the binding of certain compounds has been identified
- Identification of high sensitivity binders: OMass found binders that would have been lost in cell test noise
Rosamond Deegan, CEO of OMass, said: “The discovery of new binders for Gasdermin has proven to be unattainable by other companies and methodologies to date. Our OdyssION™ platform allowed us to interrogate GSDMD in the context of its ecosystem and allowed us to explore its interactions without the bewildering complexity of the cell.The progress we have made in identifying inhibitors for this target is very exciting and really highlights the power of our platform.
For more information, please contact:
|Mass therapy||Consilium Strategic Communications|
|Rosamond Deegan, President and CEO
Telephone: +44 (0) 1235 527589
Email: [email protected]
|Sue Charles / Chris Gardner / Kumail Waljee
Telephone: +44 (0)20 3709 5700
Email: [email protected]
About OMass Therapeutics
OMass Therapeutics is a biotechnology company identifying drugs against highly validated target ecosystems such as membrane proteins or intracellular complexes. The company’s unique technology platform includes novel biochemistry techniques, next-generation native mass spectrometry and personalized chemistry. This allows OMass to interrogate not only the target, but also how it interacts with its native ecosystem, regardless of the bewildering complexity of the cell. The result is cell system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs.
Based in Oxford, UK, OMass is backed by leading syndicate of investors, Syncona and Oxford Science Enterprises, having closed a Series A funding round of approximately $60 million.
To learn more, visit www.omass.com. Follow us on LinkedIn and Twitter